133 related articles for article (PubMed ID: 38367816)
1. Comprehensive phenotypic and genomic characterization of venous malformations.
Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E
Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816
[TBL] [Abstract][Full Text] [Related]
2. Genetic landscape of common venous malformations in the head and neck.
Du Z; Liu JL; You YH; Wang LZ; He J; Zheng JW; Zhang ZY; Wang YA
J Vasc Surg Venous Lymphat Disord; 2021 Jul; 9(4):1007-1016.e7. PubMed ID: 33248299
[TBL] [Abstract][Full Text] [Related]
3. Somatic Activating PIK3CA Mutations Cause Venous Malformation.
Limaye N; Kangas J; Mendola A; Godfraind C; Schlögel MJ; Helaers R; Eklund L; Boon LM; Vikkula M
Am J Hum Genet; 2015 Dec; 97(6):914-21. PubMed ID: 26637981
[TBL] [Abstract][Full Text] [Related]
4. CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations.
Moneghini L; Tosi D; Graziani D; Caretti A; Colletti G; Baraldini V; Cattaneo E; Spaccini L; Zocca A; Bulfamante GP
Hum Pathol; 2020 May; 99():98-106. PubMed ID: 32272124
[TBL] [Abstract][Full Text] [Related]
5. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
[TBL] [Abstract][Full Text] [Related]
6. Somatic TEK variant with intraarticular venous malformation and knee hemarthrosis treated with rapamycin.
Adham S; Revencu N; Mestre S; Nou-Howaldt M; Vernhet-Kovacsik H; Quéré I
Mol Genet Genomic Med; 2022 Jun; 10(6):e1931. PubMed ID: 35426265
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
[TBL] [Abstract][Full Text] [Related]
8. A xenograft model for venous malformation.
Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
[TBL] [Abstract][Full Text] [Related]
9. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
[TBL] [Abstract][Full Text] [Related]
10. Somatic PIK3CA mutations as a driver of sporadic venous malformations.
Castel P; Carmona FJ; Grego-Bessa J; Berger MF; Viale A; Anderson KV; Bague S; Scaltriti M; Antonescu CR; Baselga E; Baselga J
Sci Transl Med; 2016 Mar; 8(332):332ra42. PubMed ID: 27030594
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive targeted next-generation sequencing in patients with slow-flow vascular malformations.
Nozawa A; Fujino A; Yuzuriha S; Suenobu S; Kato A; Shimizu F; Aramaki-Hattori N; Kuniyeda K; Sakaguchi K; Ohnishi H; Aoki Y; Ozeki M
J Hum Genet; 2022 Dec; 67(12):721-728. PubMed ID: 36171295
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
13. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
14. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.
Wei Y; Lin S; Zhi W; Chu T; Liu B; Peng T; Xu M; Ding W; Cao C; Wu P
J Med Virol; 2023 Mar; 95(3):e28656. PubMed ID: 36905114
[TBL] [Abstract][Full Text] [Related]
15. Functional assessment of two variants of unknown significance in TEK by endothelium-specific expression in zebrafish embryos.
Bell LM; Holm A; Matysiak U; Driever W; Rößler J; Schanze D; Wieland I; Niemeyer CM; Zenker M; Kapp FG
Hum Mol Genet; 2021 Dec; 31(1):10-17. PubMed ID: 34254124
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for capillary-venous malformations.
Zerbib L; Ladraa S; Fraissenon A; Bayard C; Firpion M; Venot Q; Protic S; Hoguin C; Thomas A; Fraitag S; Duong JP; Kaltenbach S; Balducci E; Lefevre C; Villarese P; Asnafi V; Broissand C; Goudin N; Nemazanyy I; Autret G; Tavitian B; Legendre C; Arzouk N; Minard-Colin V; Chopinet C; Dussiot M; Adams DM; Mirault T; Guibaud L; Isenring P; Canaud G
Signal Transduct Target Ther; 2024 Jun; 9(1):146. PubMed ID: 38880808
[TBL] [Abstract][Full Text] [Related]
17. Development of Molecular Therapies for Venous Malformations.
Kangas J; Nätynki M; Eklund L
Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():6-19. PubMed ID: 29668117
[TBL] [Abstract][Full Text] [Related]
18. AKT/FOXO1 axis links cross-talking of endothelial cell and pericyte in TIE2-mutated venous malformations.
Si Y; Huang J; Li X; Fu Y; Xu R; Du Y; Cheng J; Jiang H
Cell Commun Signal; 2020 Aug; 18(1):139. PubMed ID: 32867785
[TBL] [Abstract][Full Text] [Related]
19. Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care.
Pirozzi F; Berkseth M; Shear R; Gonzalez L; Timms AE; Sulc J; Pao E; Oyama N; Forzano F; Conti V; Guerrini R; Doherty ES; Saitta SC; Lockwood CM; Pritchard CC; Dobyns WB; Novotny E; Wright JNN; Saneto RP; Friedman S; Hauptman J; Ojemann J; Kapur RP; Mirzaa GM
Brain; 2022 Apr; 145(3):925-938. PubMed ID: 35355055
[TBL] [Abstract][Full Text] [Related]
20. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.
Kobialka P; Sabata H; Vilalta O; Gouveia L; Angulo-Urarte A; Muixí L; Zanoncello J; Muñoz-Aznar O; Olaciregui NG; Fanlo L; Esteve-Codina A; Lavarino C; Javierre BM; Celis V; Rovira C; López-Fernández S; Baselga E; Mora J; Castillo SD; Graupera M
EMBO Mol Med; 2022 Jul; 14(7):e15619. PubMed ID: 35695059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
